A detailed history of Tower Research Capital LLC (Trc) transactions in Acumen Pharmaceuticals, Inc. stock. As of the latest transaction made, Tower Research Capital LLC (Trc) holds 3,910 shares of ABOS stock, worth $6,138. This represents 0.0% of its overall portfolio holdings.

Number of Shares
3,910
Previous 26,488 85.24%
Holding current value
$6,138
Previous $64,000 85.94%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$2.22 - $3.54 $50,123 - $79,926
-22,578 Reduced 85.24%
3,910 $9,000
Q2 2024

Aug 13, 2024

BUY
$2.14 - $4.01 $53,666 - $100,562
25,078 Added 1778.58%
26,488 $64,000
Q1 2024

May 15, 2024

SELL
$2.97 - $4.64 $82,206 - $128,430
-27,679 Reduced 95.15%
1,410 $5,000
Q4 2023

Feb 13, 2024

BUY
$1.86 - $4.48 $50,147 - $120,785
26,961 Added 1266.96%
29,089 $111,000
Q3 2023

Nov 14, 2023

SELL
$4.15 - $9.72 $6,005 - $14,064
-1,447 Reduced 40.48%
2,128 $8,000
Q2 2023

Aug 14, 2023

BUY
$3.59 - $6.59 $1,985 - $3,644
553 Added 18.3%
3,575 $17,000
Q1 2023

May 09, 2023

SELL
$3.75 - $6.65 $937 - $1,662
-250 Reduced 7.64%
3,022 $12,000
Q4 2022

Feb 10, 2023

SELL
$4.81 - $10.17 $23,304 - $49,273
-4,845 Reduced 59.69%
3,272 $18,000
Q3 2022

Nov 10, 2022

BUY
$4.44 - $10.48 $18,790 - $44,351
4,232 Added 108.93%
8,117 $81,000
Q2 2022

Aug 15, 2022

BUY
$3.08 - $4.88 $4,096 - $6,490
1,330 Added 52.05%
3,885 $18,000
Q1 2022

May 12, 2022

SELL
$3.91 - $6.73 $15,514 - $26,704
-3,968 Reduced 60.83%
2,555 $10,000
Q4 2021

Feb 14, 2022

BUY
$6.54 - $15.31 $38,115 - $89,226
5,828 Added 838.56%
6,523 $44,000
Q3 2021

Nov 15, 2021

BUY
$14.5 - $20.28 $10,077 - $14,094
695 New
695 $10,000

Others Institutions Holding ABOS

About Acumen Pharmaceuticals, Inc.


  • Ticker ABOS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 40,503,100
  • Market Cap $63.6M
  • Description
  • Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for the treatment of Alzheimer's disease. The company focuses on advancing a targeted immunotherapy drug candidate ACU193, a humanized monoclonal antibody that is in Phase I clinical-stage to target soluble amyloid-beta oligomers. Acumen Ph...
More about ABOS
Track This Portfolio

Track Tower Research Capital LLC (Trc) Portfolio

Follow Tower Research Capital LLC (Trc) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Tower Research Capital LLC (Trc), based on Form 13F filings with the SEC.

News

Stay updated on Tower Research Capital LLC (Trc) with notifications on news.